Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma

Osman Sütcüoğlu¹, Ahmet Özet², Ozan Yazıcı², Nuriye Özdemir²

Affiliations

¹ Department of Medical Oncology, Gazi University, Ankara 06200, Türkiye. Electronic address: sutcuogluo@gmail.com.
² Department of Medical Oncology, Gazi University, Ankara 06200, Türkiye.

PMID: 36174625
DOI: 10.1016/S1470-2045(22)00547-2

Comment

Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma

Osman Sütcüoğlu et al. Lancet Oncol. 2022 Oct.

. 2022 Oct;23(10):e444.

doi: 10.1016/S1470-2045(22)00547-2.

Authors

Osman Sütcüoğlu¹, Ahmet Özet², Ozan Yazıcı², Nuriye Özdemir²

Affiliations

¹ Department of Medical Oncology, Gazi University, Ankara 06200, Türkiye. Electronic address: sutcuogluo@gmail.com.
² Department of Medical Oncology, Gazi University, Ankara 06200, Türkiye.

PMID: 36174625
DOI: 10.1016/S1470-2045(22)00547-2

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma - Authors' reply.
Pautier P, Tanguy ML, Archambaud B. Pautier P, et al. Lancet Oncol. 2022 Oct;23(10):e445. doi: 10.1016/S1470-2045(22)00563-0. Lancet Oncol. 2022. PMID: 36174626 No abstract available.

Comment on

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, Bardet A, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, Archambaud B, Duffaud F; French Sarcoma Group. Pautier P, et al. Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11. Lancet Oncol. 2022. PMID: 35835135 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma

Affiliations

Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources